Enterprise Value
10.71B
Cash
850.1M
Avg Qtr Burn
-65.91M
Short % of Float
0.00%
Insider Ownership
1.42%
Institutional Own.
39.27%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details Blood cancer, Cancer, Multiple myeloma | Approved Quarterly sales | |
CARVYKTI (cilta-cel) [sNDA] Details Blood cancer, Cancer, Multiple myeloma | sNDA Acceptance for review | |
LB1908 (targeting Claudin 18.2) Details Cancer, Esophageal cancer, Pancreatic cancer, Gastric cancer | Phase 1 Update | |
LB1901 (antiCD4) Details Cancer, T-cell lymphoma | Failed Discontinued |